A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...

Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

Light therapy could be a useful treatment for the most common form of age-related macular degeneration, a new study says.

Age-related macular degeneration is the most common cause ... Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD [MARINA] and Anti-VEGF Antibody for the Treatment ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

Related Outcomes may vary by drug used to treat macular degeneration Age-related macular degeneration affects 20 million U.S. adults, study estimates New technologies, treatments could slow vision ...

Age-related macular degeneration (AMD) is associated with a higher risk for rheumatoid arthritis (RA), according to a study published online Sept. 9 in Scientific Reports. Je Moon Yoon, from ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

This NMA bridges the gap between trials for both therapies and compare them to one another based on existing data.